SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is actively trending, with its community demonstrating strong conviction and calling to 'hold' amidst current market volatility, anticipating a significant breakout. Many perceive it as 'digital silver' poised for substantial long-term growth, with discussions highlighting its foundational role and developments like LitVM and Omnichain features for earning yield.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

Ongoing CME margin hikes and impending Chinese export restrictions are driving significant volatility and intense debate around SLV. The community is sharply divided between those anticipating a continued silver squeeze fueled by industrial demand and those fearing market manipulation and a potential sharp pullback in the highly contested paper market.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as investors anticipate a potential rebound with the close of year-end tax loss selling, coupled with ongoing speculation about Elon Musk's future actions regarding X payments. The community shows a strong divide, with many asserting its status as the 'King meme coin' and envisioning significant price appreciation, while others express skepticism about its immediate trajectory.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for NEREUS, its motion sickness drug, marking the first new medication in this category in nearly 40 years. The community is highly optimistic, anticipating its significant potential to address GLP-1 associated nausea and sparking strong speculation of a major pharmaceutical buyout. With several additional pipeline catalysts on the horizon, many view the stock as deeply undervalued and poised for substantial future upside.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending due to its exceptionally active and dedicated community, which passionately advocates for the "OG meme" narrative of Rage Comics. This committed base is consistently building out an ecosystem with projects like RageMaker and RageGames, aiming to onboard new users into crypto while expressing strong conviction for significant long-term growth and widespread recognition, often positioning themselves against other meme coins for the top trending spot.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics is surging with immense trading volume following news of a proposed business combination with Applied Digital's cloud division, forming an AI compute platform called ChronoScale. This pivot into AI infrastructure, combined with the stock's low float, is driving aggressive price action and high price targets among community members. However, some discussions highlight potential significant dilution for existing shareholders, creating a divided outlook on its long-term implications amidst the short-term volatility.

Function is building the financial infrastructure that makes Bitcoin productive, unlocking yield, liquidity, and capital efficiency for holders across DeFi and traditional finance. FBTC turns Bitcoin into an asset that works.  FBTC represents the first omnichain Bitcoin yield asset, enabling BTC holders to participate in structured, risk-managed and programmatic yield strategies. FBTC is fully backed on a 1:1 basis with BTC, Bitcoin Reserve Address List is public and can be verified at any time. FBTC combines the security of Bitcoin reserves with the flexibility of smart contracts, creating a secure and efficient bridge between the Bitcoin network and modern DeFi protocols.  FBTC turns idle BTC into a functional and productive asset. The primary purpose of FBTC is to bring native Bitcoin liquidity into DeFi. Enabling Bitcoin holders to access a wide range of yield generating strategies, without having to sell their BTC. This not only enhances the utility of BTC but also allows holders to earn returns on their assets, making FBTC a powerful tool for maximizing the potential of Bitcoin in the DeFi ecosystem

Function ƒBTC

FBTC is trending amid ongoing volatility in the Bitcoin ETF market, characterized by recent outflows followed by a modest reversal of inflows. The community remains sharply divided, with some anticipating a prolonged "crypto winter" and further declines, while others maintain a bullish long-term outlook, emphasizing Bitcoin's historical resilience against market fluctuations.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind Corp is actively discussed following the FDA's recent approval of FUROSCIX for pediatric use and new patents for its ReadyFlow Autoinjector, with a key PDUFA date for the autoinjector set for July 26, 2026. While many anticipate significant revenue growth from these developments and Afrezza's international expansion, a vocal segment of the community remains highly skeptical, citing past commercialization challenges and expressing strong dissatisfaction with current leadership.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull (BULL) is trending due to significant year-end tax loss harvesting and persistent selling pressure from initial SPAC investors, which continues to drive down its share price. The community is sharply divided; bulls emphasize the company's profitability and international growth potential as a long-term accumulation opportunity, drawing comparisons to early fintech successes. Conversely, bears highlight ongoing dilution and concerns over the stock's performance, questioning its fundamental value.

Featured in Matt Furies latest book Cortex Vortex as Ratos nemesis. The character is also part of ZOGZ which confirms its real name.  Matt Furie, the artist best known for creating Pepe the Frog, has been working on a new book. The news comes from his editor, who goes by the handle @beuys_on_sale_ on Instagram. In a recent post, the editor hinted at an upcoming project featuring new characters named Gasspas and Rato. Gasspas’s visual appearance can be inferred from the artwork. In one illustration, Gasspas is depicted looming over two rats (Rato and Wat), gazing down at them in a menacing way (an image that has circulated among collectors). This inferred that Gasspas is Ratos nemesis in the new book Cortex Vortex reinforced by community quips that “cats eat rats”. Gasspas debuted as part of ZOGZ, a collection of 111 original NFT character illustrations by Matt Furie launched in May 2023.

Gasspas

Gasspas ($GASS) is trending amidst active community discussion, fueled by recent visibility on Dextools and strong 'HODL' sentiment. Many investors are captivated by its potential for significant growth, often drawing parallels to $PEPE due to shared creator involvement, while others vocalize skepticism and concerns about its trajectory. The project also garnered attention for recent charitable donations to a cat adoption center, reinforcing its community-centric meme coin identity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Simplify Asset Management Inc. Purchases Shares of 290,000 COMPASS Pathways PLC Sponsored ADR $CMPS

Simplify Asset Management Inc. acquired a new position in shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) during the third quarter, according to the company in its most...

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report) have been given an average recommendation of "Moderate Buy" by the nine brokerages that are covering the stock, MarketBeat...

<ul class="summary-bullets"><li>With an estimated 51.5 million U.S. adults suffering from mental illness and the psychedelic drug market projected to grow at a 15% CAGR to nearly $13 billion by 2035</li><li>&nbsp;Both Compass Pathways and Mind Medicine are positioned to tap a massive unmet need.</li><li>Mind Medicine leads in retail sentiment, cash runway into 2028, and late-stage progress with MM120, while Compass Pathways’ COMP360 could reach the market sooner.</li></ul>After years on the fringes of mainstream medicine, psychedelic drugmakers are suddenly finding themselves in the spotlight.Shares of companies developing psychedelic-based therapies surged this year, buoyed by a gradual softening of regulatory resistance, growing political support, and a string of company-specific catalysts. Positive clinical trial readouts, renewed investor appetite, and a pickup in merger-and-acquisition chatter have all helped fuel momentum across the space.As optimism builds around the therapeutic potential of psychedelics to treat conditions ranging from depression to PTSD, two names have stood out among the pack: Compass Pathways and Mind Medicine. Here’s a closer look at how these two psychedelic high-fliers compare — and what’s driving their rise.<h2 class="st-heading-2">Psychedelics Turn Mainstream</h2>Stymied by regulatory roadblocks, research into hallucinogenic compounds remained largely dormant for decades. However, a gradual regulatory thaw and a growing mental-health crisis have sparked renewed scientific interest. Psychedelics such as psilocybin, MDMA, and LSD are moving into the mainstream of psychological research, backed by robust clinical trials and growing institutional support.&nbsp;The psychedelics drug market is expected to grow at a compounded annual growth rate (CAGR) of 15% to nearly $13 billion in 2035 from $3 billion in 2025,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.rootsanalysis.com/reports/global-psychedelic-therapeutics-market.html">according</a> to Business Research and Consulting Group Roots Analysis.<img src="https://news.stocktwits-cdn.com/Psychedelics_Market_png_7463be0aca.webp" alt="Psychedelics Market.png">Source: Roots AnalysisThe&nbsp;<a href="https://stocktwits.com/symbol/PSIL">AdvisorShares Psychedelics ETF (PSIL)</a> has outperformed the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, which tracks the broader S&amp;P 500 Index.<img src="https://news.stocktwits-cdn.com/PSIL_Vs_SPY_png_168a676f0b.webp" alt="PSIL Vs SPY.png">Source: Koyfin<h2 class="st-heading-2">What Has Turned The Tide?</h2>This class of drugs has received strong backing from high-profile personalities, including Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Dr. Martin Makary. Kennedy has previously&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mnmd-stock-soars-after-rfk-jr-confirmed-as-hhs-chief/ch5iJvpRH6">advocated</a> for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca.As an extension, the FDA has accorded top priority to review MDMA and other psychedelics, even mulling accelerated approval for these drugs.&nbsp;Big pharma name AbbVie announced an agreement to acquire Gilgamesh Pharmaceuticals' novel psychedelic therapy candidate, bretisilocin, in August for up to $1.2 billion, lending credence to this class of medication. Atai, a biotech developing treatments for mental health, merged with Beckley Psytech, bringing Beckley's BPL-003, an investigational therapy for treatment-resistant depression (TRD) and alcohol use disorder (AUD), into its pipeline. ATAI Beckley’s stock has gained 220% this year.<h2 class="st-heading-2">Compass Pathways Vs. Mind Medicine</h2>Mind Medicine stock has returned about 110% year-to-date, compared with the 84% gain for Mind Medicine.<img src="https://news.stocktwits-cdn.com/MNMD_Vs_CMPS_png_35ac2a510a.webp" alt="MNMD Vs CMPS.png">Source: KoyfinThe primary draw for these stocks lies in the sheer size of the market opportunity. In a presentation, Mind Medicine highlighted that roughly 51.5 million adults in the U.S. are affected by mental illness, underscoring the vast and largely underserved demand for effective treatments.Mind Medicines’ lead candidate MM120 orally disintegrating tablet (ODT) is in late-stage trials for major depressive disorder (MDD). Topline data from the study is due in mid-2026. Delving into the upcoming catalysts, CEO Rob Barrow said in the third-quarter earnings release:<blockquote>“We plan to initiate Ascend, our second Phase 3 study in MDD, in mid-2026 and remain focused on advancing toward FDA submissions in both generalized anxiety disorder (GAD) and major depressive disorder (MDD). With multiple anticipated Phase 3 topline data readouts ahead, 2026 is set to be the most significant year in our history to date. ”</blockquote>Mind Medicine reported no revenue and a net loss of $67.3&nbsp;million for the three months ended Sept. 30, 2025. On the other hand, Compass Pathways’ net loss stood at $137.72 million for the September quarter,&nbsp;compared with a loss of $38.50 million a year&nbsp;earlier.London-based Compass Pathways’ lead candidate COMP360, a synthetic formulation of psilocybin that is in late-stage clinical trials for treating mental health conditions, primarily treatment-resistant depression (TRD). CEO Kabir Nath said in the earnings release that the company was moving up the expected launch timing for COMP360 in TRD by 9 to 12 months. The company&nbsp;intends to file for approval by the second half of 2026.&nbsp;<h2 class="st-heading-2">MNMD Vs. CMPS: Cash Position</h2>Mind Medicine has beefed up its cash position with a recent offering. It said its cash, cash equivalents, and investments as of September 30, 2025 ($209.1 million), along with the net proceeds of $242.8 million from the recently completed offering, will be sufficient to fund the operations into 2028. Meanwhile, Compass Pathways had a smaller cash reserve at a comparable point, but the company said it would be enough to fund operating expenses and capital expenditures through 2027.<img src="https://news.stocktwits-cdn.com/Cash_Position_Sufficient_For_Medium_Term_png_e0ea50d775.webp" alt="Cash_Position_Sufficient_For_Medium_Term.png">Source: Fiscal.ai<h2 class="st-heading-2">MNMD Vs. CMPS: How Retail’s Positioned</h2>Retail traders, however, are favorably disposed to Mind Medicine. On Stocktwits, retail sentiment toward the stock has been ‘bullish’ as of early Wednesday.<figure class="image"><img style="aspect-ratio:712/439;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_24_at_8_37_12_AM_png_3de00ad9f2.webp" alt="Screenshot 2025-12-24 at 8.37.12 AM.png" width="712" height="439"></figure>Compass Pathways, meanwhile, attracted ‘neutral’ sentiment among retailers, with sentiment showing volatility throughout the year.<figure class="image"><img style="aspect-ratio:721/436;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_24_at_8_39_54_AM_png_d4c6176ec9.webp" alt="Screenshot 2025-12-24 at 8.39.54 AM.png" width="721" height="436"></figure>According to Koyfin, the average analyst price target for Mind Medicine stock is $28.67, implying 105% upside potential. All 13 analysts covering the stock have either a ‘Buy’ or a ‘Strong Buy’ rating on the stock. Compass Pathways stock, meanwhile,&nbsp;has 144% upside potential, based on the average price target of $16.82. All but one of the 11 analyst covering the stock has bullish ratings.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-revamps-robotaxi-website-revamp-how-competition-stacks-up/cLesMvuREv3">Tesla Signals Robotaxi Expansion With Website Revamp — Here’s How The Competition Stacks Up</a>

 Creative image of an Hallucinogenic mushroom. (Representative image courtesy of Aitor Diago via Getty Images)

Psychedelics Break Out Of The Fringe Under RFK Jr’s 2025 Reset — But Did MNMD Or CMPS Own The Year?

Regulatory thaw, political backing, and late-stage data are propelling psychedelic drugmakers into the biotech spotlight — with Compass Pathways and Mind Medicine leading the charge.

Equity

Regulatory thaw, political backing, and late-stage data are propelling psychedelic drugmakers into the biotech spotlight — with Compass Pathways and Mind Medicine leading the charge.


COMPASS Pathways (NASDAQ:CMPS) Trading 4.5% Higher - Still a Buy?

COMPASS Pathways (NASDAQ:CMPS) Stock Price Up 4.5% - Here's What Happened...

COMPASS Pathways (NASDAQ:CMPS) Reaches New 12-Month High - Should You Buy?

COMPASS Pathways (NASDAQ:CMPS) Reaches New 52-Week High - Still a Buy...

COMPASS Pathways (NASDAQ:CMPS) Shares Gap Up - What's Next?

COMPASS Pathways (NASDAQ:CMPS) Shares Gap Up - Here's What Happened...

Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will host a...

COMPASS Pathways PLC Sponsored ADR $CMPS Position Boosted by 22NW LP

22NW LP grew its holdings in shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) by 36.5% during the second quarter, according to its most recent Form 13F filing with the SEC...

Schroder Investment Management Group Makes New $1.53 Million Investment in COMPASS Pathways PLC Sponsored ADR $CMPS

Schroder Investment Management Group bought a new position in shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) in the second quarter, according to the company in its most...

1,075,485 Shares in COMPASS Pathways PLC Sponsored ADR $CMPS Purchased by Hsbc Holdings PLC

Hsbc Holdings PLC bought a new stake in COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange...

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

CMPS
COMPASS Pathways

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CMPS News

CMPSCOMPASS Pathways